CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexandre, J, Brown, C, Coeffic, D, Raban, N, Pfisterer, J, Mäenpää, J, Chalchal, H, Fitzharris, B, Volgger, B, Vergote, I, Pisano, C, Ferrero, A, Pujade-Lauraine, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322951/
https://www.ncbi.nlm.nih.gov/pubmed/22240800
http://dx.doi.org/10.1038/bjc.2011.593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322951/
https://www.ncbi.nlm.nih.gov/pubmed/22240800
http://dx.doi.org/10.1038/bjc.2011.593

Ejemplares similares